Reconnect Labs is a Swiss, clinical stage pharmaceutical company developing Regenerative Therapeutics™ for mental health at the forefront of neuroscience and precision psychopharmacology. Led by neuroscientists from the University of Zurich Psychiatric University Clinic (PUKZH), Reconnect translates 30 years of in-human research and clinical practice to solve for the safety, efficacy and commercialization challenges of generation 1 psychoplastogens, Reconnect originated a portfolio of psychoactive formulations for affective and neurodegenerative disorders, chronic pain and insomnia.